We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Moderna’s COVID-19 Vaccine Appears Safe in Mouse Study with Single Dose Offering Protection

By HospiMedica International staff writers
Posted on 15 Jun 2020
Print article
Illustration
Illustration
Studies in mice of Moderna, Inc.’s (Cambridge, MA, USA) COVID-19 vaccine candidate indicate that it is unlikely to increase the risk of the disease becoming more severe and only a single dose could provide protection against the novel coronavirus.

Moderna is currently conducting human trials of its COVID-19 vaccine candidate and plans to initiate final-stage trials in July that will involve 30,000 volunteers. Previous studies conducted on a vaccine for SARS, which belongs to the same family as the new virus that causes COVID-19, have suggested that such vaccines could increase the severity of the disease after the vaccinated person becomes exposed to the pathogen at a later stage, particularly among individuals who are unable to generate a sufficiently strong immune response. This risk is viewed by scientists as a significant obstacle that needs to be overcome ahead of human trials of any COVID-19 vaccines.

According to preliminary data from animal studies released by the US National Institutes of Allergy and Infectious Disease (NIAID) and Moderna, the researchers gave mice one or two shots of various doses of Moderna’s vaccine, including doses that were too weak to generate a protective immune response. After exposing the mice to the coronavirus, the researchers concluded that “sub-protective” immune responses do not result in vaccine-associated enhanced respiratory disease, a susceptibility to more severe disease in the lungs. Upon further testing, the researchers found that the vaccine induced antibody responses to block the virus from infecting cells.

According to the researchers, the vaccine also appeared to protect the lungs and noses against infection by the coronavirus without indication of any toxic effects. The team of researchers have noted that the mice which were given only a single dose of the vaccine before exposing them to the coronavirus after seven weeks were “completely protected against lung viral replication,” indicating that a single vaccination prevented the virus from replicating in the lungs.

Related Links:
Moderna, Inc.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Mattress Replacement System
Carilex DualPlus
New
Cannulating Sphincterotome
TRUEtome

Print article

Channels

Critical Care

view channel
Image: The BrioVAD System featuring the innovative BrioVAD Pump (Photo courtesy of BrioHealth Solutions)

Innovative Ventricular Assist Device Provides Long-Term Support for Advanced Heart Failure Patients

Advanced heart failure represents the final stages of heart failure, where the heart’s ability to pump blood effectively is severely compromised. This condition often results from underlying health issues... Read more

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.